Tegaserod: A novel, selective 5-HT4 receptor partial agonist for Irritable Bowel Syndrome.
Med Channel Jan ;10(2):47-52.
Irritable bowel syndrome (IBS) is a common functional bowel disorder of unknown aetiology It is defined by the presence of gastrointestinal (GI) symptoms including abdominal pain/ discomfort, bloating and bowel motor dysfunction. No available therapy is yet effective against all the symptoms of the disorder: Current treatments therefore target individual symptoms but may be accompanied by unpleasant side-effects. Tegaserod is a novel selective serotonin receptor type-4 (5-HT4) partial agonist with structural similarity to 5-HT Tegaserod stimulates small bowel and colonic motility and helps to normalise G1 function. Clinical trials using a patient`s assessment of efficacy demonstrate that tegaserod significantly improves key symptoms of IBS: abdominal pain/discomfort, bloating and constipation. Tegaserod is well tolerated with an excellent safety profile and represents a significant treatment advance in this difficult-to-treat disorder.
PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com